Limitations on Optimal Biomarker Testing Rates

A panel of experts discuss the current limitations of optimal biomarker testing rates in the community.

EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP: 2.Strategies to Increase Biomarker Testing Rates

Now Viewing

EP: 3.Limitations on Optimal Biomarker Testing Rates

EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes

EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP: 6.NCCN Recommendations by PD-L1 Expression Level

EP: 7.Limitations of NCCN PD-L1 Expression Recommendations

EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

• What may currently limit optimal biomarker testing rates in the community?

Related Videos

Related Content

Advertisement

September 23rd 2022

A Population Health Approach to Managing Heart Failure

Related Content

Advertisement

September 23rd 2022

A Population Health Approach to Managing Heart Failure